

Announcement

Peania, October 1, 2026 – Lavipharm S.A. (the "Company") announces that it commenced sales of DUROGESIC® in the French market on Wednesday, September 30, 2026, following approval by the competent French regulatory authority of the transfer of the product's marketing authorization to the Company.

The Company is continuing the process of transferring the DUROGESIC® marketing authorizations in the remaining markets and expects the related approvals, particularly in markets of significant commercial interest, to be completed in the near term.

About Lavipharm Lavipharm (ASE: LAVI) is a pharmaceutical company focused on developing and delivering innovative healthcare solutions that advance patient care. Founded in Greece in 1911 and listed on the Athens Stock Exchange since 1995, the company has a strong presence in prescription and over-the-counter medicines in its domestic market. Lavipharm is internationally recognized for its expertise in transdermal drug delivery systems (TDDS) and maintains a global footprint through products distributed worldwide. With more than 115 years of history, Lavipharm remains committed to helping people live longer, healthier lives.

For further Information contact:

Investor Relations

Vasilis Baloumis

Tel: 210 6691 121

Email: ir@lavipharm.com